• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Motzer, R
    Hutson, T
    Cella, D
    Reeves, J
    Hawkins, Robert E
    Guo, J
    Nathan, P
    Staehler, M
    de Souza, P
    Merchan, J
    Boleti, E
    Fife, K
    Jin, J
    Jones, R
    Uemura, H
    De Giorgi, U
    Harmenberg, U
    Wang, J
    Sternberg, C
    Deen, K
    McCann, L
    Hackshaw, M
    Crescenzo, R
    Pandite, L
    Choueiri, T
    Show allShow less
    Affiliation
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.
    Issue Date
    2013-08-22
    
    Metadata
    Show full item record
    Abstract
    Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy.
    Citation
    Pazopanib versus sunitinib in metastatic renal-cell carcinoma. 2013, 369 (8):722-31 N Engl J Med
    Journal
    The New England Journal of Medicine
    URI
    http://hdl.handle.net/10541/304738
    DOI
    10.1056/NEJMoa1303989
    PubMed ID
    23964934
    Type
    Article
    Language
    en
    ISSN
    1533-4406
    ae974a485f413a2113503eed53cd6c53
    10.1056/NEJMoa1303989
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
    • Authors: Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R
    • Issue date: 2018 May 22
    • Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
    • Authors: Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H
    • Issue date: 2010 Dec
    • The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
    • Authors: Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H
    • Issue date: 2010 Oct
    • Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
    • Authors: Amaro F, Pisoeiro C, Valente MJ, Bastos ML, Guedes de Pinho P, Carvalho M, Pinto J
    • Issue date: 2022 Aug 31
    • Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
    • Authors: Annala M, Nappi L, Azad AA, Mo F, Fazli L, Chi KN, Wyatt AW
    • Issue date: 2017 Feb
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.